Showing results (201-210 of 682) with videos related to
Sort By:
Pageof 69
BMC Nephrology|August 2, 2015
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinibArun Rajasekaran, Thuy-Trang Ngo, Maen Abdelrahim, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 11, 2022
Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutationsMehrnoosh Tashakori, Joseph D Khoury, Mark J Routbort, et al.Clinical Lymphoma, Myeloma & Leukemia|June 14, 2017
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-ICarole B Miller, Rami S Komrokji, Ruben A Mesa, et al.Journal of Hematology & Oncology|December 10, 2016
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignanciesSrdan Verstovsek, Olatoyosi Odenike, Jack W Singer, et al.Blood|December 24, 2005
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemiaElihu Estey, Guillermo Garcia-Manero, Alessandra Ferrajoli, et al.Blood|March 6, 2002
Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemiaSrdan Verstovsek, Hagop Kantarjian, Taghi Manshouri, et al.Blood Advances|December 4, 2020
Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burdenDouglas Tremblay, Ruben Mesa, Bart Scott, et al.Haematologica|July 28, 2006
Mutations and promoter methylation status of NPM1 in myeloproliferative disordersYasuhiro Oki, Jaroslav Jelinek, Miloslav Beran, et al.Blood|September 27, 2013
JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasmsKoichi Takahashi, Keyur P Patel, Hagop Kantarjian, et al.Leukemia & Lymphoma|October 25, 2021
Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United StatesSrdan Verstovsek, Jingbo Yu, Robyn M Scherber, et al.Pageof 69